Trans-Hit Biomarkers - Access To Human Biospecimen Collections

By: Trans-hit Biomarkers  09-12-2011
Keywords: diseases, Biobanks, Biospecimen Collection,

Quality of biospecimen collections is crucial

Biobanks, also known as biospecimen resources, biorepositories, tissue banks, biolibraries or biological resource centers, collect and store human biological specimens such as blood or tissue from diseased and healthy subjects. These specimens can be a precious resource to support advancement of translational research.

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests. In addition, harnessing historical collections from retrospective studies may offer the benefit of expediting such valuable research and reduce costly delays and limit the need to execute lengthy, expensive validation studies, therefore dramatically accelerating clinical validation of future diagnostic products.

Types of biospecimen collections include:

  • Retrospective samples in cancer, CNS, infectious diseases, metabolic diseases, cardiovascular diseases or other specific diseases.
  • Cohort and prospective longitudinal studies in which healthy subjects have been followed for years. These collections are ideal for validating predictive biomarkers and biomarkers for early disease detection.
  • Clinical trials: These collections have been obtained using high-quality standards for sampling and storage conditions, as well as for the collection of relevant medical information (available CRF). Moreover they can be well suited for demonstrating the relevance of a given theranostic or companion biomarker.
  • Trans-Hit's Partner Network offers a global coverage which may be considered an asset to phenotypic diversity, thus offering the possibility of creating population and thematic collections.

Hundreds of biobanks exist around the world and others are created regularly. They vary in size, nature of specimen type, purpose, ethnicity, age, as well as standards of operation and extent of patient consent forms. Above all, they dramatically vary in the quality of their archived samples (storage conditions, time between sample collection and storage, storage length, associated clinical annotations, appropriate informed consent, etc.). This is why several academic and professional institutions have created organizations whose goals are to establish best practice guidelines for biospecimen collection and storage in order to improve the quality through standardization and harmonization of biorepository practice. Trans-Hit Biomarkers supports these excellent and remarkable initiatives and it believes they should be followed by all biobanks,existing and future. While Trans-Hit Biomarkers’ mission is to accelerate the validation of newly discovered biomarkers, we are trying to help both biobanks and scientists find common valuable opportunities.   

However, as poor-quality samples can only serve to jeopardize research results, it is of the utmost importance to critically select high-quality collections before starting a project. This is Trans-Hit Biomarkers' paramount impetus: carefully selecting potential partner biobanks and biospecimen collections to fully respond to the needs of researchers, and regulatory authorities.

Selection Criteria:

  • Best and evidence-based practice in both operations and research, focused on optimizing sample integrity and promoting biopreservation efforts throughout the biospecimen lifecycle
  • Well-annotated high quality clinical data sets
  • Well-established ethics framework (informed consent, ethical committees, etc.)
  • Scientific expertise.
  • Extended variety of specimens for a single subject (plasma, serum, urine, tumor, DNA, RNA, etc.)

In an effort to assist the community and to facilitate connectivity between biobanks and biomarker developers, Trans-Hit Biomarkers has established a unique biospecimen web based searching tool B4B-Hub which was during the . Scientists and biobanks can list or view biospecimen collection requests free of charge.

List of Requests for Biospecimen Collection

As this tool is offered globally, companies and academic research centers have the opportunity for real time global connectivity to hundreds of biobanks. Trans-Hit Biomarkers has built a database of more than 1.500 biobanks, including commercial biobanks. This connectivity dramatically accelerates and improves the odds for finding the ideal matching collection and scientific expertise, decreasing impediments such as existing lag times for research. Our B4B-Hub offers a convenient, expeditious, free and confidential mechanism to list on-line requests for biospecimen collections.

View Requests for Biospecimen Collections

Through the B4B-Hub, biobanks can be connected with worldwide research teams, and be regularly notified about research collaboration opportunities and  biospecimen requests aimed at increasing utilization of their expertise and biobank collections for biomarker validation.

Keywords: Biobanks, Biospecimen Collection, Biospecimen Collections, diseases,

Contact Trans-hit Biomarkers

Email - none provided

Print this page

Other products and services from Trans-hit Biomarkers


Trans-Hit Biomarkers - Unique services to TTOs and their scientists developing new biomarkers and diagnostic technologies

Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain. At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product.


Trans-Hit Biomarkers - Regulatory Services

Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy. Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.


Trans-Hit Biomarkers - Access To Animal Models

In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.


Trans-Hit Biomarkers - Proteome-Hit

By combining Trans-hit Biomarkers’ access to large high-quality biospecimen collections with Caprion’s high-throughput and quantitative multiplexed mass spectrometry assays, Proteome-Hit turns the usually expensive and time-consuming clinical validation route into a fast, cost-effective and robust process.


Trans-Hit Biomarkers - Prospective Biobanking Services

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage. Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.


Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.